🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#EHA is a space for career growth, learning, and connection, and #YoungEHA sessions are no different. From addressing burnout to hematology in outer space, this year's sessions will bring you new perspectives from the field from June 12-15. Register now: eha.fyi/EHA2025_regist…

👀

Important context for anyone watching the STARGLO ODAC or listening to our Blood Cancer Talks discussion about it in terms of the FDA’s motivation

Delighted to share our manuscript from The Lancet Haematology Commission on Adverse Events We focus on optimising assessment of toxicity and tolerability in patients receiving novel therapies Led by the fab Paul Bröckelmann thelancet.com/journals/lanha… #lymsm Florian Simon Gloria Iacoboni

Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies - The Lancet Haematology ⁦Mohamad Mohty⁩ ⁦Eddie Cliff⁩ et al. thelancet.com/journals/lanha…

The Adverse Event Reporting Series discusses measurement and analysis of adverse events, using patient-generated data to inform tolerability, and specific tolerability aspects of immunotherapies, cellular therapies, and targeted agents. Read it here: 👇 shorturl.at/fS2t4

4/ Assessing adverse events and tolerability with immunotherapy which poses special challenges. Gita Thanarajasingam Mohamad Mohty marivi mateos Surbhi Sidana, MD The Lancet Haematology thelancet.com/journals/lanha…

🧵1/ Our paper is out! A new study from the iStopMM team in JAMA Oncology shows how revising free light chain (FLC) reference intervals can reduce false positives for light chain MGUS (LC-MGUS). Let’s break it down 👇 jamanetwork.com/journals/jamao…

We have started! Chris Booth kicking off the CSO workshop with a background on what CSO is and why we exist.

So what steps can trialists, regulators, journals, editors, reviewers, sponsors & academics take to improve toxicity reporting + identification? 👇check out this figure from our The Lancet Haematology adverse event commission thelancet.com/journals/lanha… Surbhi Sidana, MD Mohamad Mohty

Clonal hematopoiesis (CH) in the ANZUP #TheraP study ASCO #ASCO25 presented by Asli Munzur ■ ¹⁷⁷Lu-PSMA-617: higher incidence of emergent CH compared to cabazitaxel chemotherapy ■ Most new clonal hematopoiesis mutations ¹⁷⁷Lu-PSMA-617 fall in DNA damage repair

🔍Presenting at #ASCO25 as a #poster and now LIVE on our website Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study Read the whole paper here: thelancet.com/journals/eclin… #TheLancet #Oncology #OncologyResearch

#mmsm #ASCO25 Oral myeloma sessions JNJ-5322- very promising trispecific (targeting BCMA and GPRC5D) New nice way for dual targeting in effort to prevent antigen escape

Helpful data, although I think we should resist the temptation to acronymise everything! #NINTS #lymsm #CARTcells

“Clinically meaningful improvement in overall survival (albeit without reaching statistical significance)” Where are the editors?! Common Sense Oncology

Conclusions from Bv-CHEP for Adult T Cell Lymphoma/Leukemia 1. High ORR & CR 2. Good Long-term survival w AlloSCT in CR1 3. It is possible to do ATLL-specific trials in the US. We can do better. Let's keep trying. onlinelibrary.wiley.com/doi/10.1111/bj… HTLV Aware #HTLV #ATLL Boston Medical Center

An absolute treat!! Great to find a kindred spirit in the drug policy world and looking forward to our long awaited project(s)!

New Systematic Review (Cancer Cell, June 2025) 💉 Low-dose PD-(L)1 for Cancer Immunotherapy Largest Review till date 📊 32 studies | 2,055 pts ✅ >65% showed ≥80% cost savings 🧬 Responses seen in HL, lung, RCC 🏥 53% studies from LMICs 🧠 Bottom line: 💸 Promising for access.

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

How physicians like me are grappling with requests for unvaccinated donor blood statnews.com/2025/06/11/unv… via STAT